US20030114762A1 - Method and system for characterization and mapping of tissue lesions - Google Patents

Method and system for characterization and mapping of tissue lesions Download PDF

Info

Publication number
US20030114762A1
US20030114762A1 US10240367 US24036702A US2003114762A1 US 20030114762 A1 US20030114762 A1 US 20030114762A1 US 10240367 US10240367 US 10240367 US 24036702 A US24036702 A US 24036702A US 2003114762 A1 US2003114762 A1 US 2003114762A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
tissue
optical
light
agent
spectral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US10240367
Other versions
US7515952B2 (en )
Inventor
Konstantinos Balas
Demetrios Pelecoudas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kreos Capital V (uk) Ltd
Original Assignee
FOUNDATION OF RESEARCH AND TECHNOLOGY AKA ITE
Forth Photonics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B1/00Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
    • A61B1/303Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the vagina, i.e. vaginoscopes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B1/00Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
    • A61B1/00163Optical arrangements
    • A61B1/00186Optical arrangements with imaging filters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B1/00Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
    • A61B1/06Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with illuminating arrangements
    • A61B1/0646Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with illuminating arrangements with illumination filters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/0059Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/0059Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0075Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/0059Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0082Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
    • A61B5/0084Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/6486Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B1/00Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
    • A61B1/04Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
    • A61B1/043Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances for fluorescence imaging
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/0059Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/0059Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0082Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
    • A61B5/0088Detecting, measuring or recording for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for oral or dental tissue
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N2021/6417Spectrofluorimetric devices
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N2021/6417Spectrofluorimetric devices
    • G01N2021/6423Spectral mapping, video display
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/21Polarisation-affecting properties

Abstract

The present invention provides a method and an apparatus for the in vivo, non-invasive, early detection of alterations and mapping of the grade of these alterations, caused in the biochemical and/or in the functional characteristics of epithelial tissues during the development of tissue atypias, dysplasias, neoplasias and cancers. The method is based, at least in part, on the simultaneous measurement of the spatial, temporal and spectral alterations in the characteristics of the light that is re-emitted from the tissue under examination, as a result of a combined tissue excitation with light and special chemical agents. The topical or systematic administration of these agents result in an evanescent contrast enhancement between normal and abnormal areas of tissue. The apparatus enables the capturing of temporally successive imaging in one or more spectral bands simultaneously. Based on the measured data, the characteristic curves that express the agent-tissue interaction kinetics, as well as numerical parameters derived from these data, are determined in any spatial point of the examined area. Mapping and characterization of the lesion, are based on these parameters.

Description

    RELATED APPLICATIONS
  • [0001]
    This application claims priority to Greek National Application Ser. No. 20000100102, filed on Mar. 28, 2000 and to United States National application Ser. No. 09/739089 filed on Dec. 15, 2000.
  • FIELD OF THE INVENTION
  • [0002]
    The present invention is directed to a method and apparatus for the in vivo, non-invasive detection and mapping of the biochemical and/or functional pathologic alterations of human tissues.
  • BACKGROUND OF THE INVENTION
  • [0003]
    Cancer precursor signs are the so-called pre-cancerous states, which are often curable if they are detected at an early stage. If left untreated, the pre-cancerous state can develop into invasive cancer, which can subsequently metastasize. At this stage, the possibilities of successful therapy are dramatically diminished. Consequently, the early detection and the objective identification of the severity of the pre-cancerous state are of crucial importance.
  • [0004]
    Conventional methods that utilize optical instruments are very limited in their ability to detect cancerous and pre-cancerous tissue lesions. This is due to the fact that the structural and metabolic changes, which take place during the development of the disease, do not significantly and specifically alter the spectral characteristics of the pathological tissue.
  • [0005]
    In order to obtain a more accurate diagnosis, biopsy samples are obtained from suspicious areas, which are submitted for histological examination. However, biopsies pose several problems, such as a) a risk for sampling errors associated with the visual limitations in detecting and localizing suspicious areas; b) a biopsy can alter the natural history of the intraepithelial lesion; c) mapping and monitoring of the lesion require multiple tissue sampling, which is subjected to several risks and limitations; and d) the diagnostic procedure performed with biopsy sampling and histologic evaluation is qualitative, subjective, time consuming, costly and labor intensive.
  • [0006]
    In recent years, a few methods and systems have been developed to overcome the disadvantages of the conventional diagnostic procedures. These methods can be classified into two categories: a) methods which are based on the spectral analysis of tissues in vivo, in an attempt to improve the diagnostic information, and b) methods which are based on the chemical excitation of tissues with the aid of special agents, which can interact with pathologic tissue and alter its optical characteristics selectively, thus enhancing the contrast between lesion and healthy tissue.
  • [0007]
    In the first case, the experimental use of spectroscopic techniques has been motivated by the ability of these techniques to detect alterations in the biochemical and/or the structural characteristics of tissue as the disease progresses. In particular, fluorescence spectroscopy has been extensively used in various tissues With the aid of a light source (usually laser) of short wave length (blue-ultraviolet range), the tissue is first excited. Next, the intensity of the fluorescent light emitted by the tissue as a function of the wavelength of the light is measured.
  • [0008]
    Garfield and Glassman in U.S. Pat. Nos. 5,450,857 and Ramanajum et al. in 5,421,339 have presented a method based on the use of fluorescence spectroscopy for the diagnosis of cancerous and pre-cancerous lesions of the cervix. The main disadvantage of fluorescence spectroscopy is that the existing biochemical modifications associated with the progress of the disease are not manifested in a direct way as modifications in the measured fluorescence spectra. The fluorescence spectra contain limited diagnostic information for two basic reasons: a) Tissues contain non-fluorescent chromophores, such as hemoglobin. Absorption by such chromophores of the emitted light from fluorophores can result in artificial dips and peaks in the fluorescence spectra. In other words the spectra carry convoluted information for several components and therefore it is difficult assess alterations in tissue features of diagnostic importance; and b) The spectra are broad because a large number of tissue components are optically excited and contribute to the measured optical signal. As a result, the spectra do not carry specific information of the pathologic alterations and thus they are of limited diagnostic value. In short, the aforementioned fluorescent technique suffers from low sensitivity and specificity in the detection and classification of tissue lesions.
  • [0009]
    Aiming to enhance the sensitivity and specificity of the preceding method, Ramanujan et al. in the Patent No. WO 98/24369 have presented a method based on the use of neural networks for the analysis of the spectral data. This method is based on the training of a computing system with a large number of spectral patterns, which have been taken from normal and from pathologic tissues. The spectrum that is measured each time is compared with the stored spectral data, facilitating in this way the identification of the tissue pathology.
  • [0010]
    R. R. Kortun et al, in U.S. Pat. No. 5,697,373, seeking to improve the quality of the measured diagnostic information, have presented a method based on the combination of fluorescence spectroscopy and Raman scattering. The latter has the ability of providing more analytical information; however, Raman spectroscopy requires complex instrumentation and ideal experimental conditions, which substantially hinders the clinical use thereof.
  • [0011]
    It is generally known that tissues are characterized by the lack of spatial homogeneity. Consequently the spectral analysis of distributed spatial points is insufficient for the characterization of their status.
  • [0012]
    Dombrowski in U.S. Pat. No. 5,424,543, describes a multi-wavelength, imaging system, capable of capturing tissue images in several spectral bands. With the aid of such a system it is possible in general to map characteristics of diagnostic importance based on their particular spectral characteristics. However, due to the insignificance of the spectral differences between normal and pathologic tissue, which is in general the case, inspection in narrow spectral bands does not allow the highlighting of these characteristics and even more so, the identification and staging of the pathologic area.
  • [0013]
    D. R. Sandison et al., in U.S. Pat. No. 5,920,399, describe an imaging system, developed for the in vivo investigation of cells, which combines multi-band imaging and light excitation of the tissue. The system also employs a dual fiber optic bundle for transmitting light from the source to the tissue, and then from the tissue to an optical detector. These bundles are placed in contact with the tissue, and various wavelengths of excitation and imaging are combined in attempt to enhance the spectral differentiation between normal and pathologic tissue.
  • [0014]
    In U.S. Pat. No. 5,921,926, J. R. Delfyett et al. have presented a method for the diagnosis of diseases of the cervix, which is based on the combination of Spectral Interferometry and Optical. Coherence Tomography (OCT). This system combines three-dimensional imaging and spectral analysis of the tissue.
  • [0015]
    Moreover, several improved versions of colposcopes have been presented, (D. R. Craine et al., U.S. Pat. Nos. 5,791,346 and K. L. Blaiz 5,989,184) in most of which, electronic imaging systems have been integrated for image capturing, analysis of tissue images, including the quantitative assessment of lesion's size. For the enhancement of the optical differentiation between normal and pathologic tissue, special agents are used in various fields of biomedical diagnostics, which are administered topically or systematically. Such agents include acetic acid solution, toluidine blue, and various photosensitizers (porphyrines) (S. Anderson Engels, C. Klinteberg, K. Svanberg, S. Svanberg, In vivo fluorescence imaging for tissue diagnostics, Phys Med. Biol. 42 (1997) 815-24). The selective staining of the pathologic tissue arises from the property of these agents to interact with the altered metabolic and structural characteristics of the pathologic area. This interaction enhances progressively and reversibly the differences in the spectral characteristics of reflection and/or fluorescence between normal and pathologic tissue. Despite the fact that the selective staining of the pathologic tissue is a dynamic phenomenon, in clinical practice the intensity and the extent of the staining are assessed qualitatively and statically. Furthermore, in several cases of early pathologic conditions, the phenomenon of temporary staining after administering the agent, is short-lasting and thus the examiner is not able to detect the alterations and even more so, to assess their intensity and extent. In other cases, the staining of the tissue progresses very slowly, resulting in patient discomfort and the creation of problems for the examiner in assessing the intensity and extent of the alterations, since they are continuously changing. The above have as direct consequence the downgrading of the diagnostic value of these diagnostic procedures. Thus, their usefulness is limited to facilitating the localization of suspected areas for obtaining biopsy samples.
  • [0016]
    Summarizing the above, the following conclusions are drawn:
  • [0017]
    a) Various conventional light dispersion spectroscopic techniques (fluorescence, elastic, non-elastic scattering, etc.) have been proposed and experimentally used for the in vivo detection of alterations in the structural characteristics of pathologic tissue. The main disadvantage of these techniques is that they provide point information, which is inadequate for the analysis of the spatially non-homogenous tissue. Multi-band imaging-has the potential to solve this problem by providing spectral information, of lesser resolution as a rule, in any spatial point of the area under examination. These imaging and non-imaging techniques, however, provide information of limited diagnostic value because the structural tissue alterations, which accompany the development of the disease, are not manifested as significant and characteristic alterations in the measured spectra. Consequently, the captured spectral information cannot be directly correlated with the tissue pathology, a fact that limits the clinical usefulness of these techniques.
  • [0018]
    b) The conventional (non-spectral) imaging techniques provide the capability of mapping characteristics of diagnostic importance in two or three dimensions. They are basically used for measuring morphological characteristics and as clinical documentation tools.
  • [0019]
    c) The diagnostic methods that are based on the selective staining of pathologic tissue with special agents allow the enhancement of the optical contrast between normal and pathologic tissue. Nevertheless they provide limited information for the in vivo identification and staging of the disease.
  • [0020]
    The selective interaction of pathologic tissue with the agents, which enhance the optical contrast with healthy tissue, is a dynamic phenomenon. It is therefore reasonable to suggest that the measurement and analysis of kinetic properties could provide important information for the in vivo detection, identification and staging of tissue lesions. In a previous publication, in which one of the inventors is a co-author, (C. Balas, A. Dimoka, E. Orfanoudaki, E. koumandakis, “In vivo assessment of acetic acid-cervical tissue interaction using quantitative imaging of back-scattered light: Its potential use for the in vivo cervical cancer detection grading and mapping”, SPIE-Optical Biopsies and Microscopic Techniques, Vol. 3568 pp. 31-37, (1998)), measurements of the alterations in the characteristics of the back-scattered light as a function of wave-length and time are presented. These alterations occur in the cervix by the topical administration of acetic acid solution. In this particular case, a general-purpose multi-spectral imaging system built around a tunable liquid crystal monochromator was used for measuring the variations in intensity of the back-scattered light as a function of time and wavelength at selected spatial points. It was found that the lineshapes of curves of intensity of back-scattered light versus time provide advanced information for the direct identification and staging of tissue neoplasias. Unpublished results of the same research team indicate that similar results can also be obtained with other agents, which have the property of enhancing the optical contrast between normal and pathologic tissue. Nevertheless, the experimental method employed in the published paper is characterized by quite a few disadvantages, such as: The imaging monochromator requires time for changing the imaging wavelength and as a consequence it is inappropriate for multispectral imaging and analysis of dynamic phenomena. It does not constitute a method for the mapping of the grade of the tissue lesions, as the presented curves illustrate the temporal alterations of intensity of the back-scattered light in selected points. The lack of data modeling and parametric analysis of kinetics data in any spatial point of the area of interest restricts the usefulness of the method in experimental studies and hinders its clinical implementation. The optics used for the imaging of the area of interest is of general purpose and does not comply with the special technical requirements for the clinical implementation of the method. Clinical implementation of the presented system is also hindered by the fact that it does not integrate appropriate means for ensuring the stability of the relative position between the tissue surface and image capturing module during the snapshot imaging procedure. This is very important since small movements of the patient (i.e. breathing) are always present during the examination procedure. If, after the application of the agent, micro-movements occur while an image is being recorded, then the spatial features of the captured images may not be accurate. This may substantially reduce the accuracy of the calculation of the curves in any spatial point that express the kinetics of marker-tissue interaction.
  • SUMMARY OF THE INVENTION
  • [0021]
    The present invention provides a method for monitoring the effects of a pathology-differentiating agent on a tissue sample. The method includes applying a pathology differentiating agent, e.g., acetic acid, on a tissue sample and measuring a spectral property, such as an emission spectrum, of the tissue sample over time, thereby monitoring the effects of a pathology differentiating agent on a tissue sample. The tissue may be a sample from: the cervix of the uterus, the vagina, the skin, the uterus, the gastrointestinal track or the respiratory track. Without intending to be limited by theory, it is believed that the pathology-differentiating agent induces transient alterations in the light scattering properties of the tissue, e.g., the abnormal epithelium.
  • [0022]
    In another aspect, the present invention features a method for the in vivo diagnosis of a tissue abnormality, e.g., a tissue atypia, a tissue dysplasia, a tissue neoplasia (such as a cervical intraepithelial neoplasia, CINI, CINII, CINIII) condylomas or cancer, in a subject. The method includes applying a pathology differentiating agent, e.g., an acetic acid solution or a combination of solutions selected from a plurality of acidic and basic solutions, to a tissue. The method further includes exposing the tissue in the subject to optical radiation, and monitoring the intensity of light emitted from the tissue over time, thereby diagnosing a tissue abnormality in a subject. The optical radiation may be broad band optical radiation, preferably polarized optical radiation.
  • [0023]
    The non-invasive methods of the present invention are useful for in vivo early detection of tissue abnormalities/alterations. The methods are also useful for mapping the grade of abnormalities/alterations in epithelial tissues during the development of tissue atypias, dysplasias, neoplasias and cancers.
  • [0024]
    In one embodiment, the tissue area of interest is illuminated with a broad band optical radiation and contacted with a pathology differentiating agent, e.g., an agent or a combination of agents which interact with pathologic tissue areas characterized by an altered biochemical composition and/or cellular functionality and provoke a transient alteration in the characteristics of the light that is re-emitted from the tissue. The light that is re-emitted from the tissue may be in the form of reflection, diffuse scattering, fluorescence or combinations or subcombinations thereof. The intensity of the light emitted from the tissue may be measured, e.g., simultaneously, in every spatial point of the tissue area of interest, at a given time point or over time (e.g., for the duration of agent-tissue interaction). A diagnosis may be made based on the quantitative assessment of the spatial distribution of alterations in the characteristics of the light re-emitted from the tissue at given time points before and after the optical and chemical excitation of the tissue. The diagnosis may also be made based on the spatial distribution of parameters calculated from kinetics curves obtained from the light re-emitted from the tissue. These curves are simultaneously measured in every spatial point of the area under examination during the optical and chemical excitation of the tissue.
  • [0025]
    In one embodiment of the invention, the step of tissue illumination comprises exposing the tissue area under analysis to optical radiation of narrower spectral width than the spectral width of the light emitted by the illumination source. In another embodiment, the step of measuring the intensity of light comprises measuring the intensity of the re-emitted light in a spectral band, the spectral width of which is narrower than the spectral width of the detector's sensitivity. In yet another embodiment, the step of measuring the intensity of light comprises measuring simultaneously the intensity of the re-emitted light in a plurality of spectral bands, the spectral widths of which are narrower than the spectral width of the detector's sensitivity.
  • [0026]
    In yet another aspect, the present invention features an apparatus for the in vivo, non-invasive early detection of tissue abnormalities/alterations and mapping of the grade of these tissue abnormalities/alterations caused in the biochemical and/or in the functional characteristics of epithelial tissues, during the development of tissue atypias, dysplasias, neoplasias and cancers. The apparatus includes optics for collecting the light re-emitted by the area under analysis, selecting magnification and focusing the image of the area. The apparatus may also include optical imaging detector(s), means for the modulation, transfer, display and capturing of the image of the tissue area of interest. In addition, the apparatus can include a computer, which has data storage, processing and analysis means, a monitor for displaying images, curves and numerical data, optics for the optical multiplication of the image of the tissue area of interest, and a light source for illuminating the area of interest. The apparatus may also include optical filters for selecting the spectral band of imaging and illumination, means for transmitting light and illuminating the area of interest, control electronics, and optionally, software for the analysis and processing of data. The software can help with the tissue image capturing and storing in specific time points and for a plurality of time points, before and after administration of the pathology-differentiating agent.
  • [0027]
    Using the foregoing apparatus, an image or a series of images may be created which express the spatial distribution of the characteristics of the kinetics of the induced alterations in the tissue's optical characteristics, before and after the administration of the agent. Pixel values of the image correspond to the spatial distribution of the alterations in the intensity of the light emitted from the tissue at given times, before and after the optical and chemical excitation of tissue. The spatial distribution of parameters may be associated with pixel gray values as a function of time. The foregoing function may be calculated from the measured and stored images and for each row of pixels with the same spatial coordinates.
  • [0028]
    In one embodiment, the step of optical filtering the imaging detector comprises an optical filter that is placed in the optical path of the rays that form the image of the tissue, for the recording of temporally successive images in a selected spectral band, the spectral width of which is narrower than the spectral width of the detector's sensitivity.
  • [0029]
    In yet another embodiment, the image multiplication optics includes light beam splitting optics that creates two identical images of the area of interest. The images are recorded by two imaging detectors, in front of which optical filters are placed. The filters are capable of transmitting light having a spectral width that is shorter than the spectral width of the detector's sensitivity, so that two groups of temporally successive images of the same tissue area are recorded simultaneously, each one corresponding to a different spectral band.
  • [0030]
    In another embodiment, the image multiplication optics include more than one beam splitter for the creation of multiple identical images of the area of interest. The images are recorded by multiple imaging detectors, in front of which optical filters are placed. The filters have different transmission characteristics and are capable of transmitting light of spectral width shorter than the spectral width of the detector's sensitivity. Thus, multiple groups of temporally successive images of the same tissue area are recorded simultaneously, each one corresponding to a different spectral band.
  • [0031]
    In a further embodiment, the image multiplication optics comprise one beam splitter for the creation of multiple identical images of the area of interest, which are recorded by multiple imaging detectors, in front of which optical filters are placed with, preferably, different transmission characteristics and capable of transmitting light of spectral width shorter than the spectral width of the detector's sensitivity, so that multiple groups of temporally successive images of the same tissue area are recorded simultaneously, each one corresponding to a different spectral band.
  • [0032]
    In yet a further embodiment, the image multiplication optics include one beam splitter for the creation of multiple identical images of the area of interest, which are recorded in different sub-areas of the same detector. Optical filters having different transmission characteristics are placed in the path of the split beams. The filters are capable of transmitting light of spectral width shorter than the spectral width of the detector's sensitivity. Multiple groups of temporally successive images of the same tissue area are recorded simultaneously in the different areas of the detector, each one corresponding to a different spectral band.
  • [0033]
    In another embodiment, the step of filtering the light source comprises an optical filter, which is placed in the optical path of an illumination light beam, and transmits light of spectral width shorter than the spectral width of sensitivity of the detector used.
  • [0034]
    In a further embodiment, the step of filtering the light source includes providing a plurality of optical filters and a mechanism for selecting the filter that is disposed in the path of the illumination light, thus enabling the tuning of the center wavelength and the spectral width of the light illuminating the tissue.
  • [0035]
    In another embodiment, the mapping of the grade of the alterations associated with the biochemical and/or functional characteristics of the tissue area of interest is based on the pixel values of one image from the group of the recorded temporally successive images of the tissue area of interest.
  • [0036]
    In a further embodiment, this mapping is based on the pixel values belonging to a plurality of images, which are members of the group of the recorded temporally successive images of the tissue area of interest.
  • [0037]
    In another embodiment, this mapping is based on numerical data derived from the pixel values belonging to a plurality of images, which are members of the group of the recorded temporally successive images of the tissue area of interest.
  • [0038]
    In a further embodiment, a pseudo-color scale, which represents with different colors the different pixel values of the image or of the images used for the mapping of abnormal tissue areas, is used for the visualization of the mapping.
  • [0039]
    In one embodiment, the image or images are used for the in vivo detection, and identification of the borders of epithelial lesions.
  • [0040]
    In another embodiment, the pixel values of the image or of the images, which are determined for the mapping of the grade of alterations in biochemical and/or functional characteristics of tissue, are used as diagnostic indices for the in vivo identification and staging of epithelial lesions.
  • [0041]
    In yet another embodiment, the image or the images can be superimposed on the color or black and white image of the same area of tissue under examination displayed on the monitor. Abnormal tissue areas are highlighted and their borders are demarcated, facilitating the selection of a representative area for taking a biopsy sample, the selective surgical removal of the abnormal area and the evaluation of the accuracy in selecting and removing the appropriate section of the tissue.
  • [0042]
    In a further embodiment, the image or the images which are determined for the mapping of the grade of alterations in biochemical and/or functional characteristics of tissue are used for the evaluation of the effectiveness of various therapeutic modalities such as radiotherapy, nuclear medicine treatments, pharmacological therapy, and chemotherapy.
  • [0043]
    In another embodiment, the optics for collecting the light re-emitted by the area under analysis includes optomechanical components employed in microscopes used in clinical diagnostic examinations, surgical microscopes, colposcopes and endoscopes.
  • [0044]
    In one embodiment of the invention directed to colposcopy applications, the apparatus may comprise a speculum, an articulated arm onto which the optical head is attached. The optical head includes a refractive objective lens, focusing optics, a mechanism for selecting the magnification, an eyepiece, a mount for attaching a camera, and an illuminator. The speculum is attached so that the central longitudinal axis of the speculum is perpendicular to the central area of the objective lens. Thus, when the speculum is inserted into the vagina and fixed in it, the relative position of the image-capturing optics and of the tissue area of interest remain unaltered, regardless of micro-movements of the cervix, which are taking place during the examination of the female subject.
  • [0045]
    In a further embodiment, the apparatus may further comprise an atomizer for delivering the agent. The atomizer is attached to the articulated arm-optical head of the apparatus and in front of the vaginal opening, where the spraying of the tissue may be controlled and synchronized with a temporally successive image capturing procedure with the aid of electronic control means.
  • [0046]
    In another embodiment of the apparatus of the invention, the image capturing detector means and image display means include a camera system. The camera system has a detector with a spatial resolution greater than 1000×1000 pixels and a monitor of
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0047]
    [0047]FIG. 1 is a schematic representation of the present method's basic principle. at least 17 inches/43.18 cm (diagonal), so that high magnification is ensured together with a large field of view while the image quality is maintained.
  • [0048]
    In a further embodiment directed to microscopes used in clinical diagnostic examinations surgical microscopes and colposcopes, a system includes an articulated arm onto which the optical hand is attached. The optical head includes an objective lens, focusing optics, a mechanism for selecting the magnification, an eyepiece, a mount for attaching a camera, an illuminator and two linear polarizers. One linear polarizer is disposed in the obptical path of the illuminating light beam and the other in the optical path of the rays, that form the image of the tissue. The polarization planes of these polarizers may be rotated. When the planes are perpendicular to each other, the contribution of the tissue's surface reflection to the formed image is eliminated.
  • [0049]
    In another embodiment directed to endoscopy, an endoscope may include optical means for transferring light from the light source to the tissue surface. The optical means may also allow the collection and transferring of rays along substantially the same axis. The optical means also al low the focusing of the rays that form the image of the tissue. The endoscope may also include two linear polarizers. One linear polarizer is disposed in the optical path of the illuminating light beam and the other in the optical path of the rays that form the image of the tissue. The polarization planes of these polarizers may be rotated. When the planes are perpendicular to each other, the contribution of the tissue's surface reflection to the formed image is eliminated.
  • [0050]
    In another embodiment, microscopes used in clinical diagnostic examinations, surgical microscopes and colposcopes may include a reflective objective lens that replaces a retroactive lens. The reflective objective lens is contracted so that a second reflection mirror is disposed in the central part of its optical front aperture. In the rear, non-reflective part of this mirror, illumination means are attached from which light is emitted toward the object. With or without illumination zooming and focusing optics, the central ray or the emitted light cone is coaxial with the central ray of the light-beam that enters the imaging lens. With the aid of illumination zooming and focusing optics, which may be adjusted simultaneously and automatically with the mechanism for varying the magnification the optical imaging system, the illuminated area and the field-of-view of the imaging system can vary simultaneously and proportionally. Any decrease in image brightness caused by increasing the magnification is compensated with the simultaneously zooming and focusing of the illumination beam.
  • [0051]
    Other features and advantages of the invention will he apparent from the following detailed description and claims.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0052]
    [0052]FIG. 1 is a schematic representation of the present method's basic principle.
  • [0053]
    In FIG. 1, the tissue (T), is sprayed using an atomizer (A), which contains the agent, e.g., acetic acid. At the same time, the tissue is illuminated with a source that emits light having a frequency within a specific spectral band that depends on the optical characteristics of both the agent and the tissue. The characteristics of the light emitted from the source can be controlled by choosing particular sources (LS), and optical filters (OFS). Sources of light for illuminating the tissue include light emitting diodes, and lasers.
  • [0054]
    For imaging the area of interest, light collection optics (L) may be used, which focus the image onto a two-dimensional optical detector (D). The output signal of the latter is amplified, modulated and digitized with the aid of appropriate electronics (EIS) and finally the image is displayed on a monitor (M) and stored in the data-storing means of a personal computer (PC). Between tissue (T) and detector (D), optical filters (OFI) can be interposed. The filter can be interposed for tissue (T) imaging in selected spectral bands, at which the maximum contrast is obtained between areas that are subjected to different grade of alterations in their optical characteristics after administering the appropriate agent.
  • [0055]
    Before administration of the latter, images can be obtained and used as references. After the agent has been administered, the detector (D) helps to capture images of the tissue, in successive time instances, which are then stored in the computer's data-storage means. The measuring rate is proportional to the rate at which the tissue's optical characteristics are altered, following the administration of the agent.
  • [0056]
    As used herein, an optical property, P, is a property that arises from the interaction of electromagnetic waves and a material sample, e.g., a tissue, such as a tissue within a subject. For example, the property can be the intensity of light after it interacts with matter, as manifested by an absorption, emission, or Raman spectrum. A dynamic optical property is a property that is obtained from a time-dependent optical property, P(t), and is determined from the measurement of P(t) at more than one time. For example, a dynamical optical property can be a relaxation time, or a time integral of P(t).
  • [0057]
    In FIG. 1, images of the same tissue area are schematically illustrated, which have been stored successively before and after administering the agent (STI). In these images, the black areas represent tissue areas that do not alter their optical characteristics (NAT), while the gray-white tones represent areas that alter their optical characteristics (AT), following the administration of the agent. The simultaneous capture of the intensity of the light re-emitted from every spatial point of the tissue area under analysis and in predetermined time instances, allows the calculation of the kinetics of the induced alterations.
  • [0058]
    In FIG. 1, two curves are illustrated: pixel value at position xy (Pvxy), versus time t. The curve ATC corresponds to an area where agent administration induced alterations (AT) in the tissue's optical characteristics. The curve (NATC) corresponds to an area where no alteration took place (NAT).
  • [0059]
    Each pixel, (x,y), can be associated with a pixel value, such as intensity I, which generally depends on time. For example, at time ti and pixel (x,y), the pixel value can be denoted by PVxy(ti). One useful dynamical spectral property, which can be obtained by measuring pixel value versus time at a particular pixel (x,y), is the relaxation time trel(x,y). Letting the maximum of a Pvxy versus time curve be denoted by A, then trel(x,y) satisfies PVxy(trel)=A/e, where e is the base of the natural logarithm. For example, if the pixel value versus time curve can be approximated by an exponential with relaxation rate r, PVXY(t)=A exp(−rt), where r>0, then trel(x,y)=1/r.
  • [0060]
    The calculation of these parameters (P) at every spatial point of the area under analysis allows kinetic information (KI) to be obtained, with pixel values that are correlated with these parameters. These values can be represented with a scale of pseudocolors (Pmin, Pmax), the spatial distribution of which allows for immediate optical evaluation of the intensity and extent of the induced alterations. Depending on the correlation degree between the intensity and the extent of the induced alterations with the pathology and the stage of the tissue lesion, the measured quantitative data and the derived parameters allow the mapping, the characterization and the border-lining of the lesion. The pseudocolor image of the phenomenon's kinetics (KI), which expresses the spatial distribution of one or more parameters, can be superimposed (after being calculated) on the tissue image, which is displayed in real-time on the monitor. Using the superimposed image as a guide facilitates the identification of the lesion's boundaries, for successful surgical removal of the entire lesion, or for locating suspicious areas to obtain a biopsy sample(s). Furthermore, based on the correlation of the phenomenon's kinetics with the pathology of the tissue, the measured quantitative data and the parameters that derive from them can provide quantitative clinical indices for the in vivo staging of the lesion or of sub-areas of the latter.
  • [0061]
    In some cases it is necessary to capture the kinetics of the phenomenon in more than one spectral band. This can help in the in vivo determination of illumination and/or imaging spectral bands at which the maximum diagnostic signal is obtained. Furthermore, the simultaneous imaging in more than one spectral band can assist in minimizing the contribution of the unwanted endogenous scattering, fluorescence and reflection of the tissue, to the optical signal measured by the detector. The measured optical signal comprises the optical signal generated by the marker-tissue interaction and the light emitted from the endogenous components of the tissue. In many cases, the recorded response of the components of the tissue constitutes noise since it occludes the generated optical signal, which carries the diagnostic information. Therefore, separation of these signals, based on their particular spectral characteristics, results in the maximization of the signal-to-noise ratio and consequently in the improvement of the obtained diagnostic information.
  • [0062]
    [0062]FIG. 2 illustrates a method for measuring in two spectral bands simultaneously and in any spatial point of the area under analysis, the kinetics of the alterations in the characteristics of the light emitted from the tissue, before and the after the administration of the contrast enhancing agent. The light emitted from the tissue is collected and focused by the optical imaging module (L) and allowed to pass through a beam splitting (BSP) optical element. Thus, two identical images of the tissue (T) are generated, which can be captured by two detectors (D1, D2). In front of the detector, appropriate optical filters (Ofλ1), (Ofλ2) can be placed, so that images with different spectral characteristics are captured. Besides beam splitters, optical filters, dichroic mirrors, etc., can also be used for splitting the image of the object. The detectors (D1), (D2) are synchronized so that they capture simultaneously the corresponding spectral images of the tissue (Ti)λ1), (Tiλ2) and in successive time-intervals, which are stored in the computer's data storage means. Generalizing, multiple spectral images can be captured simultaneously by combining multiple splitting elements, filters and sources.
  • [0063]
    [0063]FIG. 3 illustrates another method for capturing in different spectral bands simultaneously and in any spatial point of the area under analysis, the kinetics of the alterations in the characteristics of the light emitted from the tissue, before and the after the administration of the contrast enhancing agent. With the aid of a special prism (MIP) and imaging optics, it is possible to form multiple copies of the same image onto the surface of the same detector (D). Various optical filters (OFλ1), (OFλ2), (OFλ3), and (OFλ4), can be interposed along the length of the optical path of the rays that form the copies of the object's image, so that the multiple images correspond to different spectral areas.
  • [0064]
    For the clinical use of the methods of the invention, the different implementations of imaging described above can be integrated to conventional optical imaging diagnostic devises. Such devises are the various medical microscopes, colposcopes and endoscopes, which are routinely used for the in vivo diagnostic inspection of tissues. Imaging of internal tissues of the human body requires in most cases the illumination and imaging rays to travel along the same optical path, through the cavities of the body. As a result, in the common optical diagnostic devices the tissue's surface reflection contributes substantially to the formed image. This limits the imaging information for the subsurface characteristics, which is in general of great diagnostic importance. This problem becomes especially serious in epithelial tissues such as the cervix, larynx, and oral cavity, which are covered by fluids such as mucus and saliva. Surface reflection also obstructs the detection and the measurement of the alterations in the tissue's optical properties, induced after the administration of agents, which enhance the optical contrast between normal and pathologic tissue. More specifically, when an agent alters selectively the scattering characteristics of the pathologic tissue, the strong surface reflection that takes place in both pathologic (agent responsive) and normal (agent non responsive) tissue areas, occludes the diagnostic signal that originates from the interaction of the agent with the subsurface features of the tissue. In other words, surface reflection constitutes optical noise in the diagnostic signal degrading substantially the perceived contrast between agent responsive and agent non-responsive tissue areas.
  • [0065]
    For accurate diagnoses using the aforementioned imaging devices, appropriate optics can be used to eliminate noise arising from surface reflection. FIG. 4 illustrates a schematic diagram of a medical microscope that includes a light source (LS), a magnification selection mechanism (MS), an eyepiece (EP) and a mount for attaching the image capturing module (CA), (detector(s), readout electronics etc). To eliminate surface reflection, a pair of linear polarizers is employed. Light from the source passes through a linear polarizer (LPO) with the resulting linearly polarized light (LS) then impinging on the tissue. The surface reflected light (TS) has the same polarization plane as the incident light (Fresnel reflection). By placing another linear polarizer (IPO), oriented at a right angle with respect to the first, in the path of the light emitted from the tissue, the contribution of the surface reflected light is eliminated. The light that is not surface reflected enters the tissue, where due to multiple scattering, light polarization is randomized. Thus, a portion of the re-emitted light passes through the imaging polarization optics, carrying improved information for the subsurface features.
  • [0066]
    [0066]FIG. 5 illustrates an endoscope that includes an eyepiece (EP), which can be adapted to an electronic imaging system, and optical fibers or crystals for the transmission of both illumination and image rays. The endoscope also includes a first linear polarizer (LPO), disposed in the optical path of the illumination rays (LE), and a second polarizer (IPO), oriented at right angles to the first, disposed in the path of the light emitted by the tissue (II). The polarizer (LPO) can be disposed as shown in the figure, or, alternatively, where the light enters the endoscope (IL). In the latter case, the endoscope has to be constructed using polarization preserving crystals or fiber optics for transferring the light. If polarization preserving light transmission media are used, then the polarizers for the imaging rays can be disposed in their path, in front or in back of the eyepiece (EP).
  • [0067]
    A problem for the effective clinical implementation of the method described above involves the micro-movements of the patient, which are present during the snapshot imaging of the same tissue area. This problem is eliminated when the patient is under anesthesia (open surgery). In most cases, however, the movements of the tissue relative to the image capturing module, occurring during the successive image capturing time-course, result in image pixels, with the same image coordinates, which do not correspond to exactly the same spatial point x,y of the tissue area under examination. This problem is typically encountered in colposcopy. A method for eliminating the influence to the measured temporal data of the relative movements between tissue and image capturing module is presented below.
  • [0068]
    A colposcopic apparatus, illustrated in FIG. 6, includes an articulated arm (AA), onto which the optical head (OH) is affixed. The head (OH) includes a light source (LS), an objective lens (OBJ), an eyepiece (EP) and optics for selecting the magnification (MS). The image-capturing module is attached to the optical head (OH), through an opto-mechanical adapter. A speculum (KD), which is used to open-up the vaginal canal for the visualization of the cervix, is connected mechanically to the optical head (OH), so that its longitudinal symmetry axis (LA) is perpendicular to the central area of the objective lens (OBJ). The speculum enters the vagina and its blades are opened up compressing the side walls of the vagina. The speculum (KD), being mechanically connected with the optical head (OH), transfers any micromovement of the patient to the optical head (OH), which, being mounted on an articulated arm (AA), follows these movements. Thus the relative position between tissue and optical head remains almost constant.
  • [0069]
    An important issue that must also be addressed for the successful clinical implementation of the diagnostic method described herein is the synchronization of the application of the pathology differentiating agent with the initiation of the snapshot imaging procedure. FIG. 6, illustrates an atomizer (A) attached to the optical head of the microscope. The unit (MIC) is comprised of electronics for controlling the agent sprayer and it can incorporate also the container for storing the agent. When the unit (MIC) receives the proper command from the computer, it sprays a predetermined amount of the agent onto the tissue surface, while the same or another command initiates the snapshot image capturing procedure.
  • [0070]
    The diagnostic examination of non-directly accessible tissues located in cavities of the human body (ear, cervix, oral cavity, esophagus, colon, stomach) is performed with the aid of common clinical microscopes. In these devices, the illumination-imaging rays are near co-axial. More specifically, the line perpendicular to the exit point of light into the air, and the line perpendicular to the objective lens, form an angle of a few degrees. As a result, these microscopes operate at a specific distance from the subject (working distance), where the illuminated tissue area coincides with the field-of-view of the imaging system. These microscopes are found to be inappropriate in cases where tissue imaging through human body cavities of small diameter and at short working distances is required. These technical limitations hinder the successful clinical implementation of the method described herein. As discussed above, elimination of surface reflection results in a substantial improvement of the diagnostic information obtained from the quantitative assessment of marker-tissue interaction kinetics. If a common clinical microscope is employed as the optical imaging module, then as a result of the above-mentioned illumination-imaging geometry, multiple reflections occur in the walls of the cavity before the light reaches the tissue under analysis. Multiple reflections are more numerous in colposcopy because of the highly reflective blades of the speculum, which is inserted into the vagina to facilitate the inspection of the cervix.
  • [0071]
    If the illuminator of the imaging apparatus emits linearly polarized light, the multiple reflections randomize the polarization plane of the incident light. As discussed above, if the light impinging on the tissue is not linearly polarized, then the elimination of the contribution from the surface reflection to the image can not be effective.
  • [0072]
    [0072]FIG. 7 illustrates an optical imaging apparatus that includes a light source located at the central part of its front-aperture. With this arrangement, the central ray of the emitted light cone is coaxial with the central ray of the light beam that enters the imaging apparatus. This enables illumination rays to directly reach the tissue surface under examination before multiple reflections occur with the wall of the cavity or speculum. A reflective-objective lens is used, which includes a first reflection (1RM) and a second reflection (2RM) mirror. A light source (LS) is disposed at the rear of the second reflection mirror (2RM), together with, if required, optics for light beam manipulation such as zooming and focusing (SO). The reflective-objective lens (RO), by replacing the common refractive-objective used in conventional microscopes, provides imaging capability in cavities of small diameter with the freedom of choosing the working distance. The zooming and focusing optics of the light beam can be adjusted simultaneously with the mechanism for varying the magnification of the optical imaging system so that the illumination area and the field-of-view of the imaging system vary simultaneously and proportionally. Thus, image brightness is preserved regardless of the magnification level of the lens. The imaging-illumination geometry embodied in this optical imaging apparatus, along with the light beam manipulation options, helps to eliminate the surface reflection contribution to the image and consequently helps to efficiently implement the method described herein.
  • [0073]
    Equivalents
  • [0074]
    Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims (51)

    What is claimed:
  1. 1. Use of a differentiating agent in a method for monitoring the effects of said pathology differentiating agent on a tissue, comprising:
    administering a pathology differentiating agent to said tissue,
    exposing said tissue to broad band, continuous wave optical radiation; and
    measuring a dynamic optical property of said tissue, after said tissue has interacted with said pathology differentiating agent, wherein said dynamic optical property is obtained from at least two values of a time-dependent optical property, thereby monitoring the effects of a pathology differentiating agent on a tissue.
  2. 2. Use of a differentiating agent in a method for monitoring the effects of said pathology differentiating agent on a tissue, comprising:
    administering a pathology differentiating agent to said tissue;
    exposing said tissue to optical radiation; and
    measuring a non-fluorescent dynamic optical property of said tissue, after said tissue has interacted with said pathology differentiating agent, wherein said dynamic optical property is obtained from at least two values of a time-dependent optical property, thereby monitoring the effects of a pathology differentiating agent on a tissue.
  3. 3. Use of a differentiating agent in a method for monitoring the effects of said pathology differentiating agent on a tissue, the method comprising:
    administering a pathology differentiating agent to said tissue;
    exposing said tissue to optical radiation; and
    while exposing said tissue to optical radiation, measuring a dynamic optical property of said tissue, after said tissue been interacted with said pathology differentiating agent, wherein said dynamic optical property is obtained from at least two values of a time-dependent optical property,
    thereby monitoring the effects of a pathology differentiating agent on a tissue.
  4. 4. Use of a differentiating agent in a method for monitoring and mapping the effects of said pathology differentiating agent on a tissue, comprising:
    administering a pathology differentiating agent to said tissue;
    exposing said tissue to broad band, continuous wave optical radiation; and
    after said tissue has interacted with said pathology differentiating agent, measuring a dynamic optical property at several locations of the tissue to produce a spatial map of the tissue, wherein said dynamic optical property is obtained from at least two values of a time-dependent optical property,
    thereby monitoring and mapping the effects of a pathology differentiating agent on a tissue.
  5. 5. The use of any one of claims 1, 2, 3, or 4, further comprising measuring an optical property of said tissue before said tissue has interacted with said pathology differentiating agent.
  6. 6. The use of any one of claims 1, 2, 3, or 4, wherein said pathology differentiating agent is selected from the group consisting of an acidic solution and a basic solution.
  7. 7. The use of any one of claims 1, 2, 3, or 4, wherein said tissue is a tissue from the cervix of the uterus.
  8. 8. The use of any one of claims 1, 2, 3, or 4, wherein said tissue is a vagina tissue.
  9. 9. The use of any one of claims 1, 2, 3, or 4, wherein said tissue is a uterus tissue.
  10. 10. The use of any one of claims 1, 2, 3, or 4, wherein said tissue is selected from the group consisting of a skin tissue, an oral cavity tissue, a gastrointestinal track tissue, and a respiratory track tissue.
  11. 11. The use of a differentiating agent in a method for the in vivo diagnosis and mapping of a tissue abnormality in a subject, comprising
    administering a pathology differentiating agent to a subject;
    exposing a tissue in said subject to optical radiation; and
    while exposing said tissue to optical radiation, monitoring the dynamic optical property of said tissue after said tissue has interacted with said pathology differentiating agent, wherein said dynamic optical property is obtained from at least two values of a time-dependent optical property,
    thereby diagnosing and mapping a tissue abnormality in a subject.
  12. 12. The use of claim 11, wherein said optical radiation is broad band optical radiation.
  13. 13. The use of claim 11, wherein said optical radiation is polarized optical radiation.
  14. 14. The use of claim 11, wherein said tissue abnormality is selected from the group consisting of a tissue atypia, a tissue dysplasia, a tissue neoplasia, condylomas and cancer.
  15. 15. The use of claim 11, wherein said tissue abnormality is neoplasia of any grade.
  16. 16. The use of claim 11, wherein said tissue abnormality is a cervical intraepithelial neoplasia.
  17. 17. The use of claim 11, wherein said pathology differentiating agent is selected from the group consisting of an acidic solution and a basic solution.
  18. 18. The use of claim 11, wherein said tissue is a sample from the cervix of the uterus.
  19. 19. The use of claim 11, wherein said tissue is a vaginal tissue.
  20. 20. The use of claim 11, wherein said tissue is a uterine tissue.
  21. 21. The use of claim 11, wherein said tissue is selected from the group consisting of a skin tissue, an oral cavity tissue a gastrointestinal track tissue, and a respiratory track tissue.
  22. 22. A system for diagnosing and mapping a tissue abnormality, the system comprising a detector for measuring a difference in a dynamic optical property between a normal tissue and an abnormal tissue, said difference being caused by applying a pathology differentiating agent to the tissue.
  23. 23. The system of claim 22, further comprising an applicator for applying a pathology differentiating agent to the tissue.
  24. 24. The system of claim 23, wherein the applicator is an atomizer.
  25. 25. The system of claim 22, wherein the pathology differentiating agent is capable of altering the reflection characteristics of the abnormal tissue.
  26. 26. The system of claim 22, wherein the pathology differentiating agent is selected from the group consisting of an acidic solution and a basic solution.
  27. 27. The system of claim 22, wherein the detector is suitable for obtaining an emission spectrum for measuring the dynamic optical property of the tissue.
  28. 28. The system of claim 22, wherein the detector is suitable for measuring light emitted by the tissue for measuring the dynamic optical property of the tissue.
  29. 29. The system of claim 28, further comprising a beam splitter for splitting the light emitted by the tissue into a plurality of beams.
  30. 30. The system of claim 29, further comprising a plurality of optical filters, each of the filters transmitting over a specific spectral range, for filtering each of the plurality of beams, wherein the dynamic optical property of the tissue can be measured for each of the plurality of filtered beams.
  31. 31. The system of claim 22, further comprising a light source for shining light on the tissue to obtain the difference in the dynamic optical property.
  32. 32. The system of claim 22, wherein the light source includes at least one of a laser and a light-emitting diode.
  33. 33. The system of claim 22, wherein the light shone on the tissue is linearly polarized in a first direction.
  34. 34. The system of claim 33, further comprising a linear polarizer for polarizing light emitted from the tissue, in response to shining light thereon, in a direction substantially perpendicular to the first direction, thereby reducing a contribution of light reaching the detector arising from tissue surface reflection.
  35. 35. The system of claim 31, wherein the light source and the detector are included on an optical head.
  36. 36. The system of claim 35, further comprising a probing device connected to the optical head, said probing device coupled with the tissue so that relative motion between the tissue and the optical head is substantially eliminated.
  37. 37. The system of claim 36, wherein the tissue includes vaginal tissue, and the probing device includes a speculum for insertion into a vagina.
  38. 38. The system of claim 36, wherein the tissue includes gastrointestinal tissue or respiratory tissue, and the probing device includes an endoscope for insertion into a gastrointestinal track or a respiratory track, respectively.
  39. 39. The system of claim 36, further comprising a reflective objective lens so that the light source emits a cone of light having a symmetry axis that is substantially coaxial with a longitudinal symmetry axis of the objective lens to substantially reduce multiple reflections of light by at least one of the probing device and the tissue.
  40. 40. An apparatus for the in vivo diagnosis and mapping of a tissue abnormality comprising
    a. Optics for collecting light re-emitted by the tissue under analysis for magnification and focusing an image of the tissue;
    b. Optical imaging detector;
    c. Means for modulating, transferring, displaying and capturing of the image of the tissue;
    d. Computer which includes data storage, processing and analysis means;
    e. Monitor for displaying images, curves and numerical data;
    f. Optics for the optical multiplication of the image of the tissue;
    g. Light source consisting of broad band, continuous wave optical radiation for illuminating the tissue;
    h. Optics filters or selecting a spectral band of imaging and illumination;
    i. Means for transmitting light and illuminating the tissue;
    j. Control electronics; and
    k. Software for analyzing and processing of data, and for capturing, registering and storing of tissue images obtained at specific spectral bands and time instances, before and after administering an agent or a combination of agents that alter the optical properties of atypical and pathological tissue areas, wherein dynamic, optical properties and their spatial map is obtained from the stored images.
  41. 41. The apparatus of claim 40, wherein a pseudo-color scale, which represents different values of the dynamic optical properties with different colors, is used for the visualization of tissue areas with abnormalities of different grade.
  42. 42. The apparatus of claim 40 or 41, wherein the image is used for the selective surgical removal of the atypical and pathological tissue area.
  43. 43. The apparatus of claim 40 or 41, wherein the image is used as a guide for taking a biopsy sample.
  44. 44. The apparatus if claim 40 or 41, wherein the image is used for the in vivo detection, mapping, and determination of the borders of epithelial lesions.
  45. 45. The apparatus or claim 40 or 41, wherein the parameters determined as a function of dynamic optical properties are used as diagnostic indices for the in vivo identification, grading of epithelial lesions and for the mapping of tissue areas with epithelial lesions of different grade.
  46. 46. A system for diagnosing and mapping a tissue abnormality, the system comprising:
    a detector for measuring a difference in a dynamic optical property between a normal tissue and an abnormal tissue, said difference being caused by applying a pathology differentiating agent to the tissue;
    a light source for shining light on the tissue, wherein the light source and the detector are included on an optical head;
    a probing device connected to the optical head, said probing device coupled with the tissue so that relative motion between the tissue and the optical head is substantially eliminated; and
    an applicator for applying a pathology differentiating agent to the tissue.
  47. 47. The system of claim 46, wherein the tissue includes vaginal tissue, and the probing device includes a speculum for insertion into a vagina.
  48. 48. The system of claim 46, wherein the tissue includes gastrointestinal tissue or respiratory tissue, and the probing device includes an endoscope for insertion into a gastrointestinal track or a respiratory track, respectively.
  49. 49. The system of claim 46, further comprising
    a beam splitter for splitting the light emitted by the tissue into a plurality of beams;
    a plurality of optical filters, each of the filters transmitting over a specific spectral range, for filtering each of the plurality of beams, wherein the dynamic optical property of the tissue can be measured for each of the plurality of filtered beams.
  50. 50. The system of claim 46, wherein the light shone on the tissue is linearly polarized in a first direction.
  51. 51. The system of claim 50, further comprising a linear polarizer for polarizing light emitted from the tissue, in response to shining light thereon, in a direction substantially perpendicular to the first direction, thereby reducing a contribution of light reaching the detector arising from tissue surface reflection.
US10240367 2000-03-28 2001-03-28 System for characterization and mapping of tissue lesions Active 2023-12-28 US7515952B2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GR20000-100102 2000-03-28
GR20000100102 2000-03-28
US09/739089 2000-12-15
US09739089 US20020007123A1 (en) 2000-03-28 2000-12-15 Method and system for characterization and mapping of tissue lesions
PCT/GR2001/000017 WO2001072214A1 (en) 2000-03-28 2001-03-28 Method and system for characterization and mapping of tissue lesions
US10240367 US7515952B2 (en) 2000-03-28 2001-03-28 System for characterization and mapping of tissue lesions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10240367 US7515952B2 (en) 2000-03-28 2001-03-28 System for characterization and mapping of tissue lesions
US12368647 US7974683B2 (en) 2000-03-28 2009-02-10 Method and system for characterization and mapping of tissue lesions via light and special chemical agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12368647 Continuation US7974683B2 (en) 2000-03-28 2009-02-10 Method and system for characterization and mapping of tissue lesions via light and special chemical agents

Publications (2)

Publication Number Publication Date
US20030114762A1 true true US20030114762A1 (en) 2003-06-19
US7515952B2 US7515952B2 (en) 2009-04-07

Family

ID=40328199

Family Applications (7)

Application Number Title Priority Date Filing Date
US09739089 Abandoned US20020007123A1 (en) 2000-03-28 2000-12-15 Method and system for characterization and mapping of tissue lesions
US10240367 Active 2023-12-28 US7515952B2 (en) 2000-03-28 2001-03-28 System for characterization and mapping of tissue lesions
US10346338 Abandoned US20030163049A1 (en) 2000-03-28 2003-01-16 Method and system for characterization and mapping of tissue lesions
US10850955 Abandoned US20050054936A1 (en) 2000-03-28 2004-05-21 Method and system for characterization and mapping of tissue lesions
US10978101 Active 2023-03-29 US8173432B2 (en) 2000-03-28 2004-10-29 Method and system for characterization and mapping of tissue lesions
US11266021 Active US7598088B2 (en) 2000-03-28 2005-11-03 Optical imaging method and system for characterization and mapping of tissue lesions
US12368647 Active 2021-04-01 US7974683B2 (en) 2000-03-28 2009-02-10 Method and system for characterization and mapping of tissue lesions via light and special chemical agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09739089 Abandoned US20020007123A1 (en) 2000-03-28 2000-12-15 Method and system for characterization and mapping of tissue lesions

Family Applications After (5)

Application Number Title Priority Date Filing Date
US10346338 Abandoned US20030163049A1 (en) 2000-03-28 2003-01-16 Method and system for characterization and mapping of tissue lesions
US10850955 Abandoned US20050054936A1 (en) 2000-03-28 2004-05-21 Method and system for characterization and mapping of tissue lesions
US10978101 Active 2023-03-29 US8173432B2 (en) 2000-03-28 2004-10-29 Method and system for characterization and mapping of tissue lesions
US11266021 Active US7598088B2 (en) 2000-03-28 2005-11-03 Optical imaging method and system for characterization and mapping of tissue lesions
US12368647 Active 2021-04-01 US7974683B2 (en) 2000-03-28 2009-02-10 Method and system for characterization and mapping of tissue lesions via light and special chemical agents

Country Status (11)

Country Link
US (7) US20020007123A1 (en)
EP (2) EP1267707B1 (en)
JP (2) JP4217403B2 (en)
CN (1) CN100413460C (en)
CA (1) CA2400702C (en)
DE (1) DE60137914D1 (en)
DK (1) DK1267707T3 (en)
ES (2) ES2322235T3 (en)
FI (1) FI20021477A (en)
RU (1) RU2288636C2 (en)
WO (1) WO2001072214A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010041843A1 (en) * 1999-02-02 2001-11-15 Mark Modell Spectral volume microprobe arrays
US20030004419A1 (en) * 2001-06-28 2003-01-02 Treado Patrick J. Method for Raman chemical imaging of endogenous chemicals to reveal tissue lesion boundaries in tissue
US20040024321A1 (en) * 2002-08-05 2004-02-05 Marshik-Geurts Barbara J. Near-infrared spectroscopic analysis of blood vessel walls
US20040077950A1 (en) * 2002-08-05 2004-04-22 Marshik-Geurts Barbara J. Near-infrared spectroscopic analysis of blood vessel walls
US20040206914A1 (en) * 2003-04-18 2004-10-21 Medispectra, Inc. Methods and apparatus for calibrating spectral data
US20040206913A1 (en) * 2003-04-18 2004-10-21 Medispectra, Inc. Methods and apparatus for characterization of tissue samples
US20050131284A1 (en) * 2002-04-02 2005-06-16 Yeda Research And Development Co. Ltd. Characterization of moving objects in a stationary background
US20090221912A1 (en) * 2005-05-06 2009-09-03 Darin Nelson Imaging and analysis of movement of erythrocytes in blood vessels in relation to the cardiac cycle
US20110184272A1 (en) * 2008-06-13 2011-07-28 Kun Zeng Portable Diagnostic Device for Precancerous Lesion of Cervical Cancer
US20110190639A1 (en) * 2010-02-02 2011-08-04 Commissariat a L'Energie Atomique et Aux Energies Altematives Bi-Spectral Peroperative Optical Probe
US8005527B2 (en) 2002-07-10 2011-08-23 Luma Imaging Corporation Method of determining a condition of a tissue
US8078268B2 (en) 2001-06-28 2011-12-13 Chemimage Corporation System and method of chemical imaging using pulsed laser excitation and time-gated detection to determine tissue margins during surgery
US8403862B2 (en) 2007-12-20 2013-03-26 Yeda Research And Development Co. Ltd. Time-based imaging
US20150109617A1 (en) * 2012-04-30 2015-04-23 Mayo Foundation For Medical Education And Research Spectrometric systems and methods for improved focus localization of time- and space-varying measurements

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6847490B1 (en) * 1997-01-13 2005-01-25 Medispectra, Inc. Optical probe accessory device for use in vivo diagnostic procedures
US6826422B1 (en) * 1997-01-13 2004-11-30 Medispectra, Inc. Spectral volume microprobe arrays
WO2000037917A3 (en) * 1998-12-23 2001-08-23 Medispectra Inc Systems and methods for optical examination of samples
US6427082B1 (en) * 1998-12-23 2002-07-30 Medispectra, Incorporated Optical methods and systems for rapid screening of the cervix
US7260248B2 (en) * 1999-12-15 2007-08-21 Medispectra, Inc. Image processing using measures of similarity
US6902935B2 (en) * 1999-12-15 2005-06-07 Medispectra, Inc. Methods of monitoring effects of chemical agents on a sample
US7187810B2 (en) * 1999-12-15 2007-03-06 Medispectra, Inc. Methods and systems for correcting image misalignment
DE60138534D1 (en) * 2000-03-28 2009-06-10 Univ Texas Method and apparatus for digital diagnostic multispectral imaging
US20020007123A1 (en) 2000-03-28 2002-01-17 Constantinos Balas Method and system for characterization and mapping of tissue lesions
JP2004504615A (en) * 2000-07-20 2004-02-12 ジラ・インク Improved diagnostic methods for detecting dysplastic epithelium
US20040006274A1 (en) * 2000-10-16 2004-01-08 Cole Giller Method and apparatus for probe localization in brain matter
US6839661B2 (en) * 2000-12-15 2005-01-04 Medispectra, Inc. System for normalizing spectra
WO2006091853A3 (en) * 2001-06-28 2008-05-08 Chemimage Corp Method of chemical imaging to determine tissue margins during surgery
US7596404B2 (en) * 2001-06-28 2009-09-29 Chemimage Corporation Method of chemical imaging to determine tissue margins during surgery
GB0130862D0 (en) * 2001-12-22 2002-02-06 P W Allen & Company Ltd Method of examining potential cellular abnormalities
WO2003062799A3 (en) * 2002-01-18 2003-10-16 Newton Lab Inc Spectroscopic diagnostic methods and system
EP1482831A1 (en) * 2002-02-12 2004-12-08 Science & Engineering Associates Inc. Cancer detection and adaptive dose optimization treatment system
WO2003079093A3 (en) * 2002-03-14 2004-04-15 Science & Engineering Associat Multiple imaging system and method for designing same
US6933154B2 (en) * 2002-07-09 2005-08-23 Medispectra, Inc. Optimal windows for obtaining optical data for characterization of tissue samples
US6818903B2 (en) * 2002-07-09 2004-11-16 Medispectra, Inc. Method and apparatus for identifying spectral artifacts
US7282723B2 (en) * 2002-07-09 2007-10-16 Medispectra, Inc. Methods and apparatus for processing spectral data for use in tissue characterization
US7103401B2 (en) * 2002-07-10 2006-09-05 Medispectra, Inc. Colonic polyp discrimination by tissue fluorescence and fiberoptic probe
DE10252313B9 (en) * 2002-11-11 2006-10-19 Carl Zeiss Examination system for simultaneous direct visualization of a fluorescent label and a surrounding the fluorescent label tissue area and investigation methods thereof
US20040208385A1 (en) * 2003-04-18 2004-10-21 Medispectra, Inc. Methods and apparatus for visually enhancing images
US7469160B2 (en) * 2003-04-18 2008-12-23 Banks Perry S Methods and apparatus for evaluating image focus
US20060013454A1 (en) * 2003-04-18 2006-01-19 Medispectra, Inc. Systems for identifying, displaying, marking, and treating suspect regions of tissue
US20040208390A1 (en) * 2003-04-18 2004-10-21 Medispectra, Inc. Methods and apparatus for processing image data for use in tissue characterization
US7136518B2 (en) * 2003-04-18 2006-11-14 Medispectra, Inc. Methods and apparatus for displaying diagnostic data
US20040209237A1 (en) * 2003-04-18 2004-10-21 Medispectra, Inc. Methods and apparatus for characterization of tissue samples
US20060155178A1 (en) * 2004-03-26 2006-07-13 Vadim Backman Multi-dimensional elastic light scattering
JP4700001B2 (en) * 2003-09-19 2011-06-15 ザ ジェネラル ホスピタル コーポレイション Fluorescence polarization imaging method
CN1890557A (en) * 2003-11-28 2007-01-03 Bc肿瘤研究所 Multimodal detection of tissue abnormalities based on raman and background fluorescence spectroscopy
DE102004002918B4 (en) * 2004-01-20 2016-11-10 Siemens Healthcare Gmbh Apparatus for examination of the skin
US9314164B2 (en) 2005-10-27 2016-04-19 Northwestern University Method of using the detection of early increase in microvascular blood content to distinguish between adenomatous and hyperplastic polyps
US20070129615A1 (en) * 2005-10-27 2007-06-07 Northwestern University Apparatus for recognizing abnormal tissue using the detection of early increase in microvascular blood content
US20070179368A1 (en) * 2005-10-27 2007-08-02 Northwestern University Method of recognizing abnormal tissue using the detection of early increase in microvascular blood content
US20090203977A1 (en) * 2005-10-27 2009-08-13 Vadim Backman Method of screening for cancer using parameters obtained by the detection of early increase in microvascular blood content
US20050234526A1 (en) * 2004-04-14 2005-10-20 Gilhuly Terence J Systems and methods for detection of disease including oral scopes and ambient light management systems (ALMS)
US7697576B2 (en) * 2004-05-05 2010-04-13 Chem Image Corporation Cytological analysis by raman spectroscopic imaging
WO2006005022A3 (en) * 2004-06-30 2006-06-15 Chemimage Corp Dynamic chemical imaging of biological cells and other subjects
WO2006036149A1 (en) * 2004-09-28 2006-04-06 Zila Pharmaceuticals, Inc. Methods for detecting abnormal epithelial tissue
WO2006039797A1 (en) * 2004-10-12 2006-04-20 Led Medical Diagnostics, Inc. Systems and methods relating to colposcopic viewing tubes for enhanced viewing andexamination
US8795195B2 (en) * 2004-11-29 2014-08-05 Senorx, Inc. Graphical user interface for tissue biopsy system
JP4602825B2 (en) * 2005-04-18 2010-12-22 オリンパスメディカルシステムズ株式会社 Image display device
JP5020945B2 (en) * 2005-06-06 2012-09-05 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム oct using spectrally decomposed bandwidth
US8125648B2 (en) 2006-06-05 2012-02-28 Board Of Regents, The University Of Texas System Polarization-sensitive spectral interferometry
US20060281068A1 (en) * 2005-06-09 2006-12-14 Chemimage Corp. Cytological methods for detecting a disease condition such as malignancy by Raman spectroscopic imaging
EP1738682B1 (en) * 2005-07-01 2008-02-13 Ecole Polytechnique Electronic polarimetric imaging system for colposcopy device
WO2007022196A3 (en) * 2005-08-15 2007-09-27 Univ Texas Needle biopsy imaging system
US8945197B1 (en) 2005-10-24 2015-02-03 Lockheed Martin Corporation Sight-restoring visual prosthetic and method using infrared nerve-stimulation light
US8956396B1 (en) 2005-10-24 2015-02-17 Lockheed Martin Corporation Eye-tracking visual prosthetic and method
US7749162B2 (en) * 2005-09-29 2010-07-06 Forth Photonics Ltd. Vaginal speculum arrangement
DK1769731T3 (en) * 2005-09-29 2009-07-06 Forth Photonics Ltd Vaginalspekulum
US9011509B2 (en) 2007-11-30 2015-04-21 Lockheed Martin Corporation Individually optimized performance of optically stimulating cochlear implants
US20070129630A1 (en) * 2005-12-07 2007-06-07 Shimko Daniel A Imaging method, device and system
EP1969992B1 (en) * 2005-12-28 2012-05-02 Olympus Medical Systems Corp. Image processing device and image processing method in the image processing device
US20080045799A1 (en) * 2006-04-10 2008-02-21 Peter Whitehead Multipurpose diseased tissue detection devices, systems, and methods
DE102006022878B3 (en) * 2006-05-15 2007-09-06 Sartorius Biotech Gmbh Acquiring an image of a sample in a transparent longitudinal sample vessel comprises illuminating the sample and/or vessel using a first illuminating arrangement, recording a first image of the sample and further processing
WO2007143141B1 (en) * 2006-06-01 2008-07-03 Gen Hospital Corp In-vivo optical imaging method including analysis of dynamic images
US8340745B2 (en) 2006-06-05 2012-12-25 Forth Photonics Ltd. Methods for characterizing cancer and pre-cancer tissues
US8065802B2 (en) * 2006-07-14 2011-11-29 The Gillette Company Shaving razor
US20080077200A1 (en) * 2006-09-21 2008-03-27 Aculight Corporation Apparatus and method for stimulation of nerves and automated control of surgical instruments
US20080118886A1 (en) * 2006-11-21 2008-05-22 Rongguang Liang Apparatus for dental oct imaging
CN101541231B (en) * 2006-11-21 2012-01-11 皇家飞利浦电子股份有限公司 A system for imaging of tissue in an anatomical structure
EP2086396A1 (en) * 2006-11-21 2009-08-12 Philips Electronics N.V. A system, device, method, computer-readable medium, and use for in vivo imaging of tissue in an anatomical structure
JP5506395B2 (en) * 2006-12-19 2014-05-28 コーニンクレッカ フィリップス エヌ ヴェ Photoacoustic and ultrasound of conjugated imaging system
WO2010093503A9 (en) * 2007-01-05 2011-03-03 Myskin, Inc. Skin analysis methods
US20090245603A1 (en) * 2007-01-05 2009-10-01 Djuro Koruga System and method for analysis of light-matter interaction based on spectral convolution
EP2099363A4 (en) * 2007-01-05 2012-01-04 Myskin Inc System, device and method for dermal imaging
US8012189B1 (en) 2007-01-11 2011-09-06 Lockheed Martin Corporation Method and vestibular implant using optical stimulation of nerves
CA2941213A1 (en) * 2007-01-19 2008-07-24 Sunnybrook Health Sciences Centre Imaging probe with combined ultrasound and optical means of imaging
US7883536B1 (en) 2007-01-19 2011-02-08 Lockheed Martin Corporation Hybrid optical-electrical probes
CN101622538B (en) * 2007-02-14 2012-09-26 宝丽化学工业有限公司 Method of supporting the differentiation of horny layer cells
US20090076368A1 (en) * 2007-04-11 2009-03-19 Forth Photonics Ltd. Integrated imaging workstation and a method for improving, objectifying and documenting in vivo examinations of the uterus
US7951075B2 (en) * 2007-04-23 2011-05-31 Olympus Medical Systems Corp. Inspection method with endoscope
EP2237190A2 (en) * 2007-08-03 2010-10-06 STI Medical Systems, LLC Computerized image analysis for a acetic acid induced cervical intraepithelial neoplasia
CA2724973C (en) 2008-05-20 2015-08-11 University Health Network Device and method for fluorescence-based imaging and monitoring
US8416405B2 (en) * 2008-08-08 2013-04-09 Chemimage Corporation Raman chemical imaging of implantable drug delivery devices
US8253936B2 (en) * 2008-08-08 2012-08-28 Chemimage Corporation Raman characterization of transplant tissue
CN102282569A (en) * 2008-10-10 2011-12-14 国际科学技术医疗系统有限责任公司 Tissue Classification Methods cervical Imaging
JP4697289B2 (en) * 2008-11-05 2011-06-08 ソニー株式会社 Imaging apparatus, display control method of the imaging apparatus
US20100130969A1 (en) * 2008-11-25 2010-05-27 Apogen Technologies, Inc. System and method for dermatological treatment
US9241622B2 (en) * 2009-02-12 2016-01-26 Alcon Research, Ltd. Method for ocular surface imaging
US9232889B2 (en) * 2009-02-12 2016-01-12 Alcon Research, Ltd. Method and apparatus for ocular surface imaging
JP2012524276A (en) * 2009-04-14 2012-10-11 ザ ジェネラル ホスピタル コーポレーションThe General Hospitalcorporation Method and apparatus for imaging living body tissue to the multimodal
US8063385B2 (en) * 2009-05-29 2011-11-22 General Electric Company Method and apparatus for ultraviolet scan planning
US8484922B2 (en) * 2010-02-17 2013-07-16 Sealed Air Corporation (Us) Alkaline and heat resistant foam composite and floor underlayment
JP4879374B2 (en) * 2010-05-19 2012-02-22 オリンパスメディカルシステムズ株式会社 The endoscope and an endoscope apparatus
DE102010021534A1 (en) * 2010-05-19 2011-11-24 Eberhard-Karls-Universität Tübingen Universitätsklinikum Direct testing of biological material ex vivo
EP2596456A4 (en) * 2010-07-21 2017-11-08 Diopsys Inc Method and system for analyzing optical coherence tomography (oct) results using color reflectivity discretization analysis
GB201014783D0 (en) * 2010-09-06 2010-10-20 St George S Hospital Medical School Apparatus and method for positioning a probe for observing microcirculation vessels
US9208556B2 (en) * 2010-11-26 2015-12-08 Quantitative Insights, Inc. Method, system, software and medium for advanced intelligent image analysis and display of medical images and information
US20120165681A1 (en) * 2010-12-23 2012-06-28 Tyco Healthcare Group Lp Delineating Skin or Surface Lesions
JP5912134B2 (en) * 2011-01-21 2016-04-27 アルコン リサーチ, リミテッド Optical coherence tomography, surgery end probe combined lighting or photocoagulation
US20130046153A1 (en) * 2011-08-16 2013-02-21 Elwha LLC, a limited liability company of the State of Delaware Systematic distillation of status data relating to regimen compliance
EP2757933A4 (en) 2011-09-22 2015-07-01 Univ George Washington Systems and methods for visualizing ablated tissue
US9084611B2 (en) 2011-09-22 2015-07-21 The George Washington University Systems and methods for visualizing ablated tissue
CA2858610A1 (en) * 2011-12-21 2013-06-27 Catherine M. Shachaf System for imaging lesions aligning tissue surfaces
WO2013109130A1 (en) * 2012-01-18 2013-07-25 Sanchez Joel Gerardo Diaz Colpostereoscope for photodynamic diagnosis (pdd) of diseases of the female genital tract and early detection of neoplastic lesions
JP6144915B2 (en) * 2012-01-30 2017-06-07 キヤノン株式会社 Reconstruction method of a tissue image acquisition method and device
JP2017000838A (en) * 2012-06-01 2017-01-05 ソニー株式会社 Medical apparatus and control method
WO2014039323A1 (en) * 2012-09-04 2014-03-13 Ninepoint Medical, Inc. A low cost molded optical probe with astigmatic correction, fiber port, low back reflection, and highly reproducible in manufacturing quantities
JP6223460B2 (en) * 2012-10-18 2017-11-01 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. Apparatus for the analysis system, a method of using the analysis system and the device having the device
US9471892B2 (en) * 2013-03-14 2016-10-18 Profiles International, Inc. System and method for embedding report descriptors into an XML string to assure report consistency
WO2014168734A1 (en) 2013-03-15 2014-10-16 Cedars-Sinai Medical Center Time-resolved laser-induced fluorescence spectroscopy systems and uses thereof
US9844318B2 (en) 2013-03-26 2017-12-19 Novartis Ag Devices, systems, and methods for calibrating an OCT imaging system in a laser surgical system
CN103750810B (en) * 2013-12-30 2015-10-07 深圳市理邦精密仪器股份有限公司 Methods colposcopy to characterize the image acquisition means and
DE202014102353U1 (en) 2014-05-20 2014-05-27 Borcad Cz S.R.O. colposcope
US9757182B2 (en) * 2014-06-02 2017-09-12 Biosense Webster (Israel) Ltd. Identification and visualization of gaps between cardiac ablation sites
USD788786S1 (en) * 2014-07-31 2017-06-06 The Mathworks, Inc. Display screen or portion thereof with color graphical user interface
GB201414631D0 (en) * 2014-08-18 2014-10-01 Univ Singapore Apparatus and methods for simultaneous multimodal nonlinear optical microscopy for label-free bio-imaging
CA2998699A1 (en) * 2015-09-23 2017-03-30 Novadaq Technologies ULC Methods and systems for assessing healing of tissue
US9895112B2 (en) * 2016-05-04 2018-02-20 National Chung Cheng University Cancerous lesion identifying method via hyper-spectral imaging technique
RU169745U1 (en) * 2016-06-21 2017-03-30 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр Институт прикладной физики Российской академии наук" (ИПФ РАН) Optoacoustic microscope for bioimaging

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235984A (en) * 1992-03-30 1993-08-17 Hewlett-Packard Company On-line acoustic densitometry tool for use with an ultrasonic imaging system
US5842995A (en) * 1996-06-28 1998-12-01 Board Of Regents, The Univerisity Of Texas System Spectroscopic probe for in vivo measurement of raman signals
US6101408A (en) * 1996-08-22 2000-08-08 Western Research Company, Inc. Probe and method to obtain accurate area measurements from cervical lesions
US20020007122A1 (en) * 1999-12-15 2002-01-17 Howard Kaufman Methods of diagnosing disease
US6370422B1 (en) * 1998-03-19 2002-04-09 Board Of Regents, The University Of Texas System Fiber-optic confocal imaging apparatus and methods of use
US20040111031A1 (en) * 1999-07-22 2004-06-10 Alfano Robert R. Spectral polarizing tomographic dermatoscope

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122A (en) * 1850-02-26 Dotjgall
US127735A (en) * 1872-06-11 Improvement in pruning-shears
US4071020A (en) * 1976-06-03 1978-01-31 Xienta, Inc. Apparatus and methods for performing in-vivo measurements of enzyme activity
FR2430754A1 (en) * 1978-07-13 1980-02-08 Groux Jean Endoscope ultraviolet
JPS57211109A (en) * 1981-06-22 1982-12-24 Konan Camera Kenkyusho:Kk Microscope
US5143054A (en) 1988-12-28 1992-09-01 Adair Edwin Lloyd Cervical videoscope with detachable camera unit
US5956144A (en) 1992-09-03 1999-09-21 Micro Research, Inc. Method and apparatus for use of polarized light vectors in identifying and evaluating constituent compounds in a specimen
US5424543A (en) 1993-04-19 1995-06-13 Surface Optics Corporation Imaging spectroradiometer
US5421339A (en) 1993-05-12 1995-06-06 Board Of Regents, The University Of Texas System Diagnosis of dysplasia using laser induced fluoroescence
US6159445A (en) 1994-07-20 2000-12-12 Nycomed Imaging As Light imaging contrast agents
US5450857A (en) 1994-05-19 1995-09-19 Board Of Regents, The University Of Texas System Method for the diagnosis of cervical changes
US5572608A (en) * 1994-08-24 1996-11-05 International Business Machines Corporation Sinc filter in linear lumen space for scanner
US5697373A (en) 1995-03-14 1997-12-16 Board Of Regents, The University Of Texas System Optical method and apparatus for the diagnosis of cervical precancers using raman and fluorescence spectroscopies
US6411835B1 (en) 1997-01-13 2002-06-25 Medispectra, Inc. Spectral volume microprobe arrays
US5995856A (en) * 1995-11-22 1999-11-30 Nellcor, Incorporated Non-contact optical monitoring of physiological parameters
US5646368A (en) 1995-11-30 1997-07-08 International Business Machines Corporation Printed circuit board with an integrated twisted pair conductor
US5647368A (en) * 1996-02-28 1997-07-15 Xillix Technologies Corp. Imaging system for detecting diseased tissue using native fluorsecence in the gastrointestinal and respiratory tract
JP3796635B2 (en) * 1996-03-06 2006-07-12 富士写真フイルム株式会社 Fluorescence detection device
US5791346A (en) 1996-08-22 1998-08-11 Western Research Company, Inc. Colposcope device and method for measuring areas of cervical lesions
US6135965A (en) 1996-12-02 2000-10-24 Board Of Regents, The University Of Texas System Spectroscopic detection of cervical pre-cancer using radial basis function networks
US5920399A (en) 1997-03-18 1999-07-06 Sandia Corporation Multispectral imaging method and apparatus
US5989184A (en) 1997-04-04 1999-11-23 Medtech Research Corporation Apparatus and method for digital photography useful in cervical cancer detection
US6081740A (en) 1997-04-23 2000-06-27 Accumed International, Inc. Method and apparatus for imaging and sampling diseased tissue
US5921926A (en) 1997-07-28 1999-07-13 University Of Central Florida Three dimensional optical imaging colposcopy
EP1071473B1 (en) 1997-10-20 2007-10-10 Board Of Regents The University Of Texas System Acetic acid as a signal enhancing contrast agent in fluorescence spectroscopy
US6134010A (en) 1997-11-07 2000-10-17 Lucid, Inc. Imaging system using polarization effects to enhance image quality
JP4383533B2 (en) * 1998-02-23 2009-12-16 フィロニクス ファーマシューティカルズ, インコーポレイテッド Using the teleost, methods of screening for agents for activity
US6332092B1 (en) 1998-07-08 2001-12-18 Lifespex, Incorporated Optical probe having and methods for uniform light irradiation and/or light collection over a volume
JP3717675B2 (en) * 1998-08-21 2005-11-16 フジノン株式会社 The endoscope light source device
US6299860B1 (en) 1998-10-15 2001-10-09 Fluoro Probe, Inc. Method for viewing diseased tissue located within a body cavity
US6292683B1 (en) * 1999-05-18 2001-09-18 General Electric Company Method and apparatus for tracking motion in MR images
US20020007123A1 (en) * 2000-03-28 2002-01-17 Constantinos Balas Method and system for characterization and mapping of tissue lesions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235984A (en) * 1992-03-30 1993-08-17 Hewlett-Packard Company On-line acoustic densitometry tool for use with an ultrasonic imaging system
US5842995A (en) * 1996-06-28 1998-12-01 Board Of Regents, The Univerisity Of Texas System Spectroscopic probe for in vivo measurement of raman signals
US6101408A (en) * 1996-08-22 2000-08-08 Western Research Company, Inc. Probe and method to obtain accurate area measurements from cervical lesions
US6370422B1 (en) * 1998-03-19 2002-04-09 Board Of Regents, The University Of Texas System Fiber-optic confocal imaging apparatus and methods of use
US20040111031A1 (en) * 1999-07-22 2004-06-10 Alfano Robert R. Spectral polarizing tomographic dermatoscope
US20020007122A1 (en) * 1999-12-15 2002-01-17 Howard Kaufman Methods of diagnosing disease

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010041843A1 (en) * 1999-02-02 2001-11-15 Mark Modell Spectral volume microprobe arrays
US20030004419A1 (en) * 2001-06-28 2003-01-02 Treado Patrick J. Method for Raman chemical imaging of endogenous chemicals to reveal tissue lesion boundaries in tissue
US8078268B2 (en) 2001-06-28 2011-12-13 Chemimage Corporation System and method of chemical imaging using pulsed laser excitation and time-gated detection to determine tissue margins during surgery
US6965793B2 (en) * 2001-06-28 2005-11-15 Chemimage Corporation Method for Raman chemical imaging of endogenous chemicals to reveal tissue lesion boundaries in tissue
US20050131284A1 (en) * 2002-04-02 2005-06-16 Yeda Research And Development Co. Ltd. Characterization of moving objects in a stationary background
US7912534B2 (en) * 2002-04-02 2011-03-22 Yeda Research And Development Co. Ltd. Characterization of moving objects in a stationary background
US8005527B2 (en) 2002-07-10 2011-08-23 Luma Imaging Corporation Method of determining a condition of a tissue
US20040024321A1 (en) * 2002-08-05 2004-02-05 Marshik-Geurts Barbara J. Near-infrared spectroscopic analysis of blood vessel walls
US20080221455A1 (en) * 2002-08-05 2008-09-11 Infraredx, Inc. Near-infrared spectroscopic analysis of blood vessel walls
US7486985B2 (en) * 2002-08-05 2009-02-03 Infraredx, Inc. Near-infrared spectroscopic analysis of blood vessel walls
US20040077950A1 (en) * 2002-08-05 2004-04-22 Marshik-Geurts Barbara J. Near-infrared spectroscopic analysis of blood vessel walls
US8060187B2 (en) 2002-08-05 2011-11-15 Infraredx, Inc. Near-infrared spectroscopic analysis of blood vessel walls
US20040206914A1 (en) * 2003-04-18 2004-10-21 Medispectra, Inc. Methods and apparatus for calibrating spectral data
US20040206913A1 (en) * 2003-04-18 2004-10-21 Medispectra, Inc. Methods and apparatus for characterization of tissue samples
US8172763B2 (en) 2005-05-06 2012-05-08 Yeda Research And Development Co., Ltd. Imaging and analysis of movement of erythrocytes in blood vessels in relation to the cardiac cycle
US20090221912A1 (en) * 2005-05-06 2009-09-03 Darin Nelson Imaging and analysis of movement of erythrocytes in blood vessels in relation to the cardiac cycle
US8403862B2 (en) 2007-12-20 2013-03-26 Yeda Research And Development Co. Ltd. Time-based imaging
US20110184272A1 (en) * 2008-06-13 2011-07-28 Kun Zeng Portable Diagnostic Device for Precancerous Lesion of Cervical Cancer
US20110190639A1 (en) * 2010-02-02 2011-08-04 Commissariat a L'Energie Atomique et Aux Energies Altematives Bi-Spectral Peroperative Optical Probe
US20150109617A1 (en) * 2012-04-30 2015-04-23 Mayo Foundation For Medical Education And Research Spectrometric systems and methods for improved focus localization of time- and space-varying measurements
US9739663B2 (en) * 2012-04-30 2017-08-22 Mayo Foundation For Medical Education And Research Spectrometric systems and methods for improved focus localization of time- and space-varying measurements

Also Published As

Publication number Publication date Type
US7598088B2 (en) 2009-10-06 grant
US20030163049A1 (en) 2003-08-28 application
CA2400702C (en) 2010-07-20 grant
US20090253991A1 (en) 2009-10-08 application
US8173432B2 (en) 2012-05-08 grant
US7974683B2 (en) 2011-07-05 grant
JP2003527915A (en) 2003-09-24 application
US20020007123A1 (en) 2002-01-17 application
US7515952B2 (en) 2009-04-07 grant
CN100413460C (en) 2008-08-27 grant
CN1419428A (en) 2003-05-21 application
US20050054936A1 (en) 2005-03-10 application
EP2057936A1 (en) 2009-05-13 application
RU2288636C2 (en) 2006-12-10 grant
EP1267707A1 (en) 2003-01-02 application
JP2008220977A (en) 2008-09-25 application
ES2322235T3 (en) 2009-06-18 grant
ES2464718T3 (en) 2014-06-03 grant
WO2001072214A1 (en) 2001-10-04 application
RU2002128728A (en) 2004-03-27 application
EP2057936B1 (en) 2014-05-07 grant
FI20021477A (en) 2002-08-14 application
DE60137914D1 (en) 2009-04-23 grant
CA2400702A1 (en) 2001-10-04 application
US20060141633A1 (en) 2006-06-29 application
DK1267707T3 (en) 2009-07-06 grant
EP1267707B1 (en) 2009-03-11 grant
JP4217403B2 (en) 2009-02-04 grant
US20050090751A1 (en) 2005-04-28 application

Similar Documents

Publication Publication Date Title
Zonios et al. Morphological model of human colon tissue fluorescence
US6241662B1 (en) Acetic acid as a signal enhancing contrast agent in fluorescence spectroscopy
US6110106A (en) Endoscopes and methods relating to direct viewing of a target tissue
US6922583B1 (en) Method for measuring tissue morphology
US6411835B1 (en) Spectral volume microprobe arrays
US7236815B2 (en) Method for probabilistically classifying tissue in vitro and in vivo using fluorescence spectroscopy
US20040073120A1 (en) Systems and methods for spectroscopy of biological tissue
Polglase et al. A fluorescence confocal endomicroscope for in vivo microscopy of the upper-and the lower-GI tract
US5687730A (en) Apparatus for detecting the presence of abnormal tissue within a target tissue beneath the skin of a patient
US6678398B2 (en) Dual mode real-time screening and rapid full-area, selective-spectral, remote imaging and analysis device and process
US7530948B2 (en) Tethered capsule endoscope for Barrett's Esophagus screening
US20080013960A1 (en) Apparatus and method for providing information for at least one structure
US6571118B1 (en) Combined fluorescence and reflectance spectroscopy
US20080015446A1 (en) Systems and methods for generating fluorescent light images
US20040111031A1 (en) Spectral polarizing tomographic dermatoscope
US20010041843A1 (en) Spectral volume microprobe arrays
US6870620B2 (en) Apparatus and method for determining tissue characteristics
US6697666B1 (en) Apparatus for the characterization of tissue of epithelial lined viscus
US5986271A (en) Fluorescence imaging system
US6826422B1 (en) Spectral volume microprobe arrays
US6537211B1 (en) Flourescence imaging endoscope
US5920399A (en) Multispectral imaging method and apparatus
EP0792618A1 (en) Imaging system for detecting diseased tissue using native fluorescence in the gastrointestinal and respiratory tract
US20070232874A1 (en) System and method for imaging the reflectance of a substrate
US20010047136A1 (en) In-vivo tissue inspection and sampling

Legal Events

Date Code Title Description
AS Assignment

Owner name: FOUNDATION OF RESEARCH AND TECHNOLOGY, A.K.A. I.T.

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BALAS, KONSTANTINOS;PELECOUDAS, DEMETROIS;REEL/FRAME:013571/0301

Effective date: 20030123

AS Assignment

Owner name: FORTH PHOTONICS LIMITED, ENGLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BALAS, CONSTANTINOS;PELECOUDAS, DEMETRIOS;FOUNDATION OF RESEARCH AND TECHNOLOGY HELLAS, THE;REEL/FRAME:016656/0111

Effective date: 20020814

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: KREOS CAPITAL V (UK) LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DYSIS MEDICAL LIMITED;REEL/FRAME:041152/0237

Effective date: 20161202

Owner name: DYSIS MEDICAL LIMITED, UNITED KINGDOM

Free format text: CHANGE OF NAME;ASSIGNOR:FORTH PHOTONICS LIMITED;REEL/FRAME:041187/0136

Effective date: 20110215

AS Assignment

Owner name: KREOS CAPITAL V (UK) LIMITED, UNITED KINGDOM

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCETO: SECURITY INTEREST PREVIOUSLY RECORDED ON REEL 041152 FRAME 0237. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST;ASSIGNOR:DYSIS MEDICAL LIMITED;REEL/FRAME:041660/0108

Effective date: 20161202